CoChat
Sign Up
Cited by 142Lipoproteins and Cardiovascular HealthAcute Ischemic Stroke ManagementAcute Myocardial Infarction Research

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)

Bohula, Erin A., Wiviott, Stephen D., Giugliano, Robert P., Blazing, Michael A., Park, Jeong-Gun, Murphy, Sabina A., White, Jennifer A., Mach, Francois, Van de Werf, Frans, Dalby, Anthony J., White, Harvey D., Tershakovec, Andrew M., Cannon, Christopher P., Braunwald, Eugene·2017·Circulation
DOI 10.1161/circulationaha.117.029095
Open this paper in CoChat — free account

Abstract

Background: Patients who experience an acute coronary syndrome are at heightened risk of recurrent ischemic events, including stroke. Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabilized after acute coronary syndrome. We investigated the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), with a focus on patients with a stroke before randomization. Methods: Patients who experienced acute coronary syndrome were randomized to a placebo/simvastatin or ezetimibe/simvastatin regimen and followed for a median of 6 years. Treatment efficacy was assessed for the entire population and by subgroups for the first and total (first and subsequent) events for the end points of stroke of any etiology, stroke subtypes, and the primary trial end point at 7 years. Results: Of 18 144 patients, 641 (3.5%) experienced at least 1 stroke; most were ischemic (527, 82%). Independent predictors of stroke included prior stroke, older age, atrial fibrillation, congestive heart failure, diabetes mellitus, myocardial infarction, and renal dysfunction. There was a nonsignificant reduction in the first event of stroke of any etiology (4.2% versus 4.8%; hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.73–1.00; P =0.052) with ezetimibe/simvastatin versus placebo/simvastatin, driven by a significant 21% reduction in ischemic stroke (3.4% versus 4.1%; HR, 0.79; 95% CI, 0.67–0.94; P =0.008) and a nonsignificant increase in hemorrhagic stroke (0.8% versus 0.6%; HR, 1.38; 95% CI, 0.93–2.04; P =0.11). Evaluating total events, including the first and all recurrent strokes, ezetimibe/simvastatin reduced stroke of any etiology (HR, 0.83; 95% CI, 0.70–0.98; P =0.029) and ischemic stroke (HR, 0.76; 95% CI, 0.63–0.91; P =0.003). Patients who had experienced a stroke prior to randomization were at a higher risk of recurrence and demonstrated an absolute risk reduction of 8.6% for stroke of any etiology (10.2% versus 18.8%; number needed to treat=12; HR, 0.60; 95% CI, 0.38–0.95; P =0.030) and 7.6% for ischemic stroke (8.7% versus 16.3%; number needed to treat=13; HR, 0.52; 95% CI, 0.31–0.86; P =0.011) with ezetimibe added to simvastatin therapy. Conclusions: The addition of ezetimibe to simvastatin in patients stabilized after acute coronary syndrome reduces the frequency of ischemic stroke, with a particularly large effect seen in patients with a prior stroke. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00202878.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.117.029095

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

Sorted by citations

Items 101–142 of 142

Related

See all

Metadata

Authors
Bohula, E. A., Wiviott, S. D., Giugliano, R. P., Blazing, M. A., Park, J.-G., Murphy, S. A., White, J. A., Mach, F., Van de Werf, F., Dalby, A. J., White, H. D., Tershakovec, A. M., Cannon, C. P., & Braunwald, E.
Affiliations
  • Brigham and Women's Hospital (US)
  • Duke Clinical Research Institute (US)
  • Cardiology Dvision, Geneva University Hospital, Switzerland (F.M.)
  • Departments of Cardiovascular Medicine and Cardiovascular Sciences, University of Leuven, Belgium (F.V.d.F.)
  • Milpark Hospital (ZA)
  • Auckland City Hospital (NZ)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • TIMI Study Group, Department of Medicine, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (E.A.B., S.D.W., R.P.G., J.-G.P., S.A.M., C.P.C., E.B.)
ORCID
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2017-12-19
Volume
136
Issue
25
Pages
2440-2450
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/circulationaha.117.029095
OpenAlex
W2757304856
Cited by
142
References
24
Citations by year
2026: 12 · 2025: 11 · 2024: 12 · 2023: 19 · 2022: 18 · 2021: 20 · 2020: 21 · 2019: 17 · 2018: 11 · 2017: 1
FWCI
14.00
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Alnylam Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Medicines Company
  • Kowa Company
  • Daiichi-Sankyo
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
ezetimibe, simvastatin, acute coronary syndrome, stroke prevention, ischemic stroke, hemorrhagic stroke, IMPROVE-IT trial, LDL cholesterol lowering, cardiovascular risk factors, stroke recurrence, secondary prevention, statin therapy, lipid-lowering therapy, atrial fibrillation, diabetes mellitus, renal dysfunction, congestive heart failure, myocardial infarction
MeSH terms
Ezetimibe, Aged, Anticholesteremic Agents, Atrial Fibrillation, Double-Blind Method, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Recurrence, Risk Factors, Placebo Effect, Proportional Hazards Models, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Stroke, Acute Coronary Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review